轩竹生物-B(02575)：NG-350A获授美国FDA快速通道资格认定

智通财经2025-10-28

智通财经APP讯，轩竹生物-B(02575)发布公告，集团从临床阶段肿瘤公司AkamisBioLtd.(Akamis)授权引进的产品NG-350A获得美国食品药品监督管理局(FDA)授予快速通道资格(FastTrackdesignation)，用于治疗错配修复功能完整(pMMR)的局部晚期直肠癌(LARC)。集团拥有NG-350A产品的大中华区开发、生产与商业化的独家权利。FDA快速通道资格认定是...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2578393801?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-28 16:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578393801","market":"fut","top_or_hot":-1,"title":"轩竹生物-B(02575)：NG-350A获授美国FDA快速通道资格认定","media":"智通财经","content":"<div>\n<p>智通财经APP讯，轩竹生物-B(02575)发布公告，集团从临床阶段肿瘤公司AkamisBioLtd.(Akamis)授权引进的产品NG-350A获得美国食品药品监督管理局(FDA)授予快速通道资格(FastTrackdesignation)，用于治疗错配修复功能完整(pMMR)的局部晚期直肠癌(LARC)。集团拥有NG-350A产品的大中华区开发、生产与商业化的独家权利。FDA快速通道资格认定是...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1361225.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>轩竹生物-B(02575)：NG-350A获授美国FDA快速通道资格认定</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n轩竹生物-B(02575)：NG-350A获授美国FDA快速通道资格认定\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-28 16:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1361225.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，轩竹生物-B(02575)发布公告，集团从临床阶段肿瘤公司AkamisBioLtd.(Akamis)授权引进的产品NG-350A获得美国食品药品监督管理局(FDA)授予快速通道资格(FastTrackdesignation)，用于治疗错配修复功能完整(pMMR)的局部晚期直肠癌(LARC)。集团拥有NG-350A产品的大中华区开发、生产与商业化的独家权利。FDA快速通道资格认定是...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1361225.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02575","symbol_name":"轩竹生物-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1361225.html","article_id":"2578393801","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578393801","pubTimestamp":1761640501,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，轩竹生物-B(02575)发布公告，集团从临床阶段肿瘤公司AkamisBioLtd.(Akamis)授权引进的产品NG-350A获得美国食品药品监督管理局(FDA)授予快速通道资格(FastTrackdesignation)，用于治疗错配修复功能完整(pMMR)的局部晚期直肠癌(LARC)。集团拥有NG-350A产品的大中华区开发、生产与商业化的独家权利。FDA快速通道资格认定是一种加速开发和审批潜在药物的方法。被授予快速通道资格认定的药物旨在治疗严重疾病并解决未满足的医疗需求，其可能是针对特定疾病的首个疗法，或与现有疗法相比更具显着临床优势，或提高现有疗法的安全性。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02575":"轩竹生物-B","NG":"NovaGold Resources Inc","BK4017":"黄金"},"translate_title":"Xuanzhu Bio-B (02575): NG-350A was granted US FDA fast track designation","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1.5,"NG":1.5},"content_text":"智通财经APP讯，轩竹生物-B(02575)发布公告，集团从临床阶段肿瘤公司AkamisBioLtd.(Akamis)授权引进的产品NG-350A获得美国食品药品监督管理局(FDA)授予快速通道资格(FastTrackdesignation)，用于治疗错配修复功能完整(pMMR)的局部晚期直肠癌(LARC)。集团拥有NG-350A产品的大中华区开发、生产与商业化的独家权利。FDA快速通道资格认定是一种加速开发和审批潜在药物的方法。被授予快速通道资格认定的药物旨在治疗严重疾病并解决未满足的医疗需求，其可能是针对特定疾病的首个疗法，或与现有疗法相比更具显着临床优势，或提高现有疗法的安全性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2578393801","isCrawlerRequest":true}